Evidence map›Paper›PMID 34079819›Full record

ArticleFrontiers in molecular biosciences2021

Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients.

Dominik Lobinger, Jens Gempt, Wolfgang Sievert, Melanie Barz, Sven Schmitt, Huyen Thie Nguyen, Stefan Stangl, Caroline Werner, Fei Wang, Zhiyuan Wu and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. ThemicroPublication biology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Dominik LobingerDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Jens GemptDepartment of Neurosurgery, School of Medicine, Technical University Munich (TUM), School of Medicine, Munich, Germany.
Wolfgang SievertDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Melanie BarzDepartment of Neurosurgery, School of Medicine, Technical University Munich (TUM), School of Medicine, Munich, Germany.
Sven SchmittDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Huyen Thie NguyenDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Stefan StanglDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Caroline WernerDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Fei WangDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Zhiyuan WuDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Hengyi FanDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Hannah ZanthDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Maxim ShevtsovDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Mathias PilzDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Isabelle RiedererDepartment of Neuroradiology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Melissa SchwabDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Jürgen SchlegelDepartment of Neuropathology, Technical University Munich (TUM), Munich, Germany.
Gabriele MulthoffDepartment of Radiation Oncology, School of Medicine, Technical University Munich (TUM), Munich, Germany.
Technical University of Munich · DEInstitute of Clinical Cancer Research · DEInstitute of Cytology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite rapid progress in the treatment of many cancers, glioblastoma remains a devastating disease with dismal prognosis. The aim of this study was to identify chaperone- and immune-related biomarkers to improve prediction of outcome in glioblastoma. Depending on its intra- or extracellular localization the major stress-inducible heat shock protein 70 (Hsp70) fulfills different tasks. In the cytosol Hsp70 interferes with pro-apoptotic signaling pathways and thereby protects tumor cells from programmed cell death. Extracellular Hsp70 together with pro-inflammatory cytokines are reported to stimulate the expression of activatory NK cell receptors, recognizing highly aggressive human tumor cells that present Hsp70 on their cell surface. Therefore, intra-, extracellular and membrane-bound Hsp70 levels were assessed in gliomas together with activatory NK cell receptors. All gliomas were found to be membrane Hsp70-positive and high grade gliomas more frequently show an overexpression of Hsp70 in the nucleus and cytosol. Significantly elevated extracellular Hsp70 levels are detected in glioblastomas with large necrotic areas. Overall survival (OS) is more favorable in patients with low Hsp70 serum levels indicating that a high Hsp70 expression is associated with an unfavorable prognosis. The data provide a first hint that elevated frequencies of activated NK cells at diagnosis might be associated with a better clinical outcome.

Indexed as

biomarkerglioblastomaHsp70NK cellspredcition of prognosistumor immunology

Identifiers

PMID34079819
PMCPMC8165168
OpenAlexW3161321578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.